Sort by

Send to

Choose Destination

Links from PubMed

Items: 19


Antigen-based immunotherapy for autoimmune disease: current status.

Hirsch DL, Ponda P.

Immunotargets Ther. 2014 Dec 16;4:1-11. doi: 10.2147/ITT.S49656. eCollection 2015. Review.


Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes.

Zhang L, Crawford F, Yu L, Michels A, Nakayama M, Davidson HW, Kappler JW, Eisenbarth GS.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2656-61. doi: 10.1073/pnas.1323436111. Epub 2014 Feb 3.


Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.

Axelsson S, Chéramy M, Akerman L, Pihl M, Ludvigsson J, Casas R.

Diabetes Care. 2013 Nov;36(11):3418-24. doi: 10.2337/dc12-2251. Epub 2013 Jul 17.


Progress in immune-based therapies for type 1 diabetes.

von Herrath M, Peakman M, Roep B.

Clin Exp Immunol. 2013 May;172(2):186-202. doi: 10.1111/cei.12085. Review.


Type 1 diabetes: primary antigen/peptide/register/trimolecular complex.

Sosinowski T, Eisenbarth GS.

Immunol Res. 2013 Mar;55(1-3):270-6. doi: 10.1007/s12026-012-8367-6. Review.


Etiopathogenesis of insulin autoimmunity.

Kanatsuna N, Papadopoulos GK, Moustakas AK, Lenmark A.

Anat Res Int. 2012;2012:457546. doi: 10.1155/2012/457546. Epub 2012 Feb 22.


Breakdown in peripheral tolerance in type 1 diabetes in mice and humans.

Jeker LT, Bour-Jordan H, Bluestone JA.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a007807. doi: 10.1101/cshperspect.a007807. Review.


Antigen-specific therapeutic approaches in Type 1 diabetes.

Clemente-Casares X, Tsai S, Huang C, Santamaria P.

Cold Spring Harb Perspect Med. 2012 Feb;2(2):a007773. doi: 10.1101/cshperspect.a007773. Review.


Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?

Phillips B, Trucco M, Giannoukakis N.

Clin Dev Immunol. 2011;2011:432016. doi: 10.1155/2011/432016. Epub 2011 Jul 18. Review.


Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?

Culina S, Boitard C, Mallone R.

Clin Dev Immunol. 2011;2011:286248. doi: 10.1155/2011/286248. Epub 2011 May 14.


Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.

Peakman M, von Herrath M.

Diabetes. 2010 Sep;59(9):2087-93. doi: 10.2337/db10-0630. No abstract available.


Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.

Rewers M, Gottlieb P.

Diabetes Care. 2009 Oct;32(10):1769-82. doi: 10.2337/dc09-0374. No abstract available.


Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

Bresson D, von Herrath M.

Diabetes Care. 2009 Oct;32(10):1753-68. doi: 10.2337/dc09-0373. No abstract available.


No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.

Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R; NBI-6024 Study Group.

Diabetes Care. 2009 Nov;32(11):2036-40. doi: 10.2337/dc09-0449. Epub 2009 Aug 18.


Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.

Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong FS, Dayan CM, Peakman M.

Clin Exp Immunol. 2009 Feb;155(2):156-65. doi: 10.1111/j.1365-2249.2008.03814.x. Epub 2008 Nov 20.


A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes.

Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, Gillis K, Brown L, Lafreniere D, Gallo M, Knox J, Hogeland K, Trucco M, Giannoukakis N.

Diabetes. 2008 Jun;57(6):1544-55. doi: 10.2337/db07-0507. Epub 2008 Mar 3.


Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands.

Petrich de Marquesini LG, Moustakas AK, Thomas IJ, Wen L, Papadopoulos GK, Wong FS.

Eur J Immunol. 2008 Jan;38(1):240-9.


Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues.

Saarelainen SA, Kinnunen TT, Buhot C, Närvänen AT, Kauppinen AK, Rytkönen-Nissinen MA, Maillere B, Virtanen TI.

Immunology. 2008 Mar;123(3):358-66. Epub 2007 Oct 16.


Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.

Staeva-Vieira T, Peakman M, von Herrath M.

Clin Exp Immunol. 2007 Apr;148(1):17-31. Review. Erratum in: Clin Exp Immunol. 2007 Jul;149(1):203.

Items per page

Supplemental Content

Write to the Help Desk